# Polypharmacy to Clozapine Monotherapy in Treatment-Resistant Schizophrenia: A Case Report and Review of the Literature

## TL;DR

A 25-year-old woman with treatment-resistant schizophrenia showed improvement after switching from multiple medications to clozapine alone.

## Contribution

This case report demonstrates the efficacy of clozapine monotherapy in managing treatment-resistant schizophrenia after long-term polypharmacy failure.

## Key findings

- The patient showed improvements in speech, communication, and eye contact after starting clozapine monotherapy.
- Clozapine monotherapy was more effective than prior polypharmacy and electroconvulsive therapy.
- The case supports broader use of clozapine to improve outcomes in treatment-resistant schizophrenia.

## Abstract

This case report discusses a 25-year-old Middle Eastern female with a 14-year history of schizophrenia, managed as an inpatient for nearly eight years. Initially referred to a psychiatrist at age 12, with one-year-long concerns about preoccupation with the idea of having a serious illness, depressed mood, decreased appetite, social withdrawal, and aggression, she underwent multiple admissions, various medication combinations, and electroconvulsive therapy but remained resistant to treatment until clozapine monotherapy was initiated in 2023.

After starting clozapine, improvements were noted in speech, communication, and eye contact, though negative symptoms and bouts of aggression persisted. This case highlights the efficacy of clozapine monotherapy in managing treatment-resistant schizophrenia after years of ineffective polypharmacy treatment.

The importance of clozapine in treating treatment-resistant schizophrenia cannot be understated. Despite its efficacy, clozapine is often underutilised globally due to concerns about adverse effects and the need for blood monitoring, leading to the overuse of antipsychotic polypharmacy. This polypharmacy is associated with higher adverse event rates, increased costs, and uncertain long-term safety.

This case report demonstrates the successful management of treatment-resistant schizophrenia with clozapine monotherapy. The patient’s significant improvement supports the need to prioritise clozapine, highlighting its benefits over polypharmacy and advocating for its broader use to enhance patient outcomes.